AIDS Patients Face Higher Risk Of HPV-Related Cancers As Immunosuppression Grows
Main Category: Cervical Cancer / HPV VaccineAlso Included In: Immune System / Vaccines; Cancer / Oncology; HIV / AIDS
Article Date: 04 Aug 2009 - 4:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Risk of human papillomavirus (HPV)-associated cancers is greater for people living with AIDS and increases with increasing immunosuppression, according to a new study published online July 31 in the Journal of the National Cancer Institute.
Although the risk of HPV-associated cancers is known to be higher among people with AIDS, the extent to which HIV-related immunosuppression plays a role is unclear.
Anil K. Chaturvedi, Ph.D., of the Infections and Immunoepidemiology Branch at the National Cancer Institute, in Rockville, Md., and colleagues used data from a cancer registry for almost 500,000 persons diagnosed with AIDS between 1980 and 2004 to estimate risks for HPV-associated cancers. These include cancers of the anus, cervix, oropharynx, penis, vagina, and vulva. The researchers also evaluated the relationship between immunosuppression and incidence of these cancers by counting CD4 T-cells at AIDS onset. Incidence was compared across three periods (1980-1989, 1990-1995, and 1996-2004).
People with AIDS had a statistically significant higher risk for all HPV-associated cancers. >From 1996 (when highly active antiretroviral therapy was introduced) through 2004, a low CD4 T-cell count was associated with an increased risk of invasive anal cancer among men. This risk was higher in 1996-2004 than in 1990-1995. Both increases in risk were statistically significant.
"Given that individuals currently infected with HIV may obtain little benefit from available HPV vaccines…our results underscore the need for effective screening for cervical cancer and anal cancer among persons with HIV infection or AIDS," the authors write.
In an accompanying editorial, Howard D. Strickler, M.D., of Albert Einstein College of Medicine, Department of Epidemiology & Population Health, said the study provides novel evidence associating HPV-related invasive cancers with the level of immunosuppression in HIV-positive patients. However, he also cautioned that while highly suggestive, the available data to date collectively still fall short of proving a biological relationship between HIV/AIDS and HPV-related cancers. Regarding the study by Chaturvedi et al, for example, after mentioning several important strengths to that study, Dr. Strickler also mentions:
"Nonetheless, it must additionally be acknowledged that these associations between human papillomavirus-related cancers and markers of immunosuppression were of moderate strength, varied between cancer types, and await confirmation."
Links:
Article
Editorial
Source
Journal of the National Cancer Institute
Visit our cervical cancer / hpv vaccine section for the latest news on this subject.
MLA
11 Feb. 2012. <http://www.medicalnewstoday.com/releases/159715.php>
APA
http://www.medicalnewstoday.com/releases/159715.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



